[1]严 晶,张 燕.DRG付费下国家谈判药品政策落地的实践[J].卫生经济研究,2021,38(12):20-21,32.
　YAN Jing,ZHANG Yan.Practice of National Negotiated Drug Policy Implementation under DRG Payment[J].Journal Press of Health Economics Research,2021,38(12):20-21,32.
点击复制

DRG付费下国家谈判药品政策落地的实践
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
38
期数:
2021年12期
页码:
20-21,32
栏目:
地市经验
出版日期:
2021-12-02

文章信息/Info

Title:
Practice of National Negotiated Drug Policy Implementation under DRG Payment
作者:
严 晶1; 张 燕1
1.浙江省宁波市医疗保障局，浙江 宁波315099
Author(s):
YAN Jing;  ZHANG Yan
Medical Security Bureau of Zhejiang Ningbo, Ningbo Zhejiang 315099, China
关键词:
国家谈判药品; DRG付费改革; 患者经济负担
Keywords:
national negotiated drugs;  DRG payment reform;  economic burden of patients
分类号:
R95
文献标志码:
A
摘要:
浙江省宁波市在DRG付费下，将国家谈判药品按实际费用折算为DRG点数进行支付，以此鼓励医生使用国家谈判药品，切实降低患者经济负担。对此，结合目前实际，提出政策建议：建立国家谈判药品监测评估机制，单独考核国家谈判抗癌药品，积极推进内科日间治疗，加强对医保定点药店的监管。
Abstract:
Under the payment of DRG, Ningbo City in Zhejiang Province converts the national negotiated drugs into DRG points based on the actual cost, so as to encourage doctors to use national negotiated drugs and effectively reduce the economic burden of patients. In this regard, in light of the current reality, policy recommendations are put forward: establish a national negotiated drug monitoring and evaluation mechanism, separately assess national negotiated on anti-cancer drugs, actively promote internal medicine day treatment, and strengthen the supervision of designated pharmacies of medical insurance.

参考文献/References:

[1] 李琛，崔丹，彭宏宇，等．谈判药品纳入医保管理的实践研究[J].中国医院管理，2018，38（5）：39-41．
[2] 朱刚令.药品谈判落地见效需把好三关[J]．中国医疗保险，2017（8）：23-25．

相似文献/References:

[1]梁 冰,王前强,陈凤磊,等.国家谈判药品对综合医院医保管理的影响及对策[J].卫生经济研究,2020,(05):42.
　LIANG Bing,WANG Qian-qiang,CHEN Feng-lei,et al.Impact of National Negotiation Drugs on Medical Insurance Management in General Hospitals and Countermeasures[J].Journal Press of Health Economics Research,2020,(12):42.
[2]陈玲玲,徐 伟,尚波波,等.国家谈判药品可获得性研究——基于苏州市公立医院采购数据的实证分析[J].卫生经济研究,2020,(12):17.
　CHEN Ling-ling,XU Wei,SHANG Bo-bo,et al.Research on the Availability of National Negotiated Drugs——An Empirical Analysis Based on the Purchasing Data of Public Hospitals in Suzhou[J].Journal Press of Health Economics Research,2020,(12):17.
[3]张钰婉,谈在祥,卢亚娟.国家谈判药品“双通道”模式实施现状及优化建议——以S市为例[J].卫生经济研究,2022,39(4):15.
　ZHANG Yu-wan,TAN Zai-xiang,LU Ya-juan.Implementation Status and Optimized Suggestions of the "Dual-Channel" Model for National Negotiation Drugs——Taking S City as An Example[J].Journal Press of Health Economics Research,2022,39(12):15.
[4]王宁锋,李雪竹,张 慧.国谈药单行支付政策研究[J].卫生经济研究,2024,41(06):16.
　WANG Ningfeng,LI Xuezhu,ZHANG Hui.Study on One-way Payment Policy for the State-negotiated Drugs[J].Journal Press of Health Economics Research,2024,41(12):16.
[5]郭孟子,李紫航,陈艺璇,等.“三医”协同视角下国谈药“双通道”高质量发展研究[J].卫生经济研究,2024,41(08):4.
　GUO Mengzi,LI Zihang,CHEN Yixuan,et al.Study on the High-quality Development of the "Dual channel" of National Negotiated Drugs from the Perspective of "Three Medical" Synergy[J].Journal Press of Health Economics Research,2024,41(12):4.
[6]罗 银,吴雨欣,杨赐然,等.湖北省国谈药可获得性研究 ——基于公立医院和零售药店的数据分析[J].卫生经济研究,2024,41(08):8.
　LUO Yin,WU Yuxin,YANG Ciran,et al.Study on the Availability of National Negotiated Drugs in Hubei Province ——Based on the Data Analysis of Public Hospitals and Retail Pharmacies[J].Journal Press of Health Economics Research,2024,41(12):8.

更新日期/Last Update: 2021-12-02